Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus radiotherapy and chemotherapy as neoadjuvant treatment for triple-negative breast cancer insensitive to initial chemotherapy
ChiCTR2600125677Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Pathological complete response. Planned start May 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600125677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125677.